Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2980 | Optifast VLCD Program Wiki | 0.71 |
| drug2355 | LithoLyte Wiki | 0.71 |
| drug2990 | Oral load of oxalate and sucralose Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
Randomized treatment trial of baking soda or LithoLyte to determine if baking soda and Litholyte are effective in raising 24 hour urine citrate and pH.
Description: Pre-to-post intervention change in 24-hour urine citrate will be measured Reference range of Urine Citrate: 18 years and older: 320-1240 mg/d 1 year and older: greater than or equal to 150 mg/g.
Measure: Change in 24 hour urine citrate Time: Pre and 24 hour post intervention (up to 90 days)Description: Pre-to-post intervention change in 24-hour urine pH will be measured Reference range of Urine pH: Age 0 days and up: 5.0-8.0
Measure: Change in 24 hour urine pH Time: Pre and 24 hour post intervention (up to 90 days)Description: Urine calcium levels will be measured post intervention. Reference range of Urine Calcium: 0-17 years: up to 6.0 mg/kg/24 hours 18 years and up: 100-300 mg/24 hours
Measure: Post-intervention 24-hour urine calcium Time: Enrollment and follow up visit (approximately 90 days)Description: Reference range of urine calcium: 0-12 years: 7-31 mg/d Male 13 years and older: 16-49 mg/d Female 13 years and older: 13-40 mg/d
Measure: 24 hour urine calcium Time: Enrollment and follow up visit (approximately 90 days)Description: Supersaturation means there are too many salts and not enough fluids in the urine. It's the driving force behind stone formation. Post interventional 24 hour urine supersaturation indices for calcium oxalate will be measured. Reference range: 0-12 years: 7-31 mg/d Male 13 years and older: 16-49 mg/d Female 13 years and older: 13-40 mg/d
Measure: Post interventional 24 hour urine supersaturation indices for calcium oxalate Time: Enrollment and follow up visit (approximately 90 days)Description: Supersaturation means there are too many salts and not enough fluids in the urine. It's the driving force behind stone formation. Post interventional 24 hour urine supersaturation indices for calcium phosphatase will be measured. Reference range: Age 18 years and up: 0.4-1.3 g/24 hour
Measure: Post interventional 24 hour urine supersaturation indices for calcium phosphatase Time: Enrollment and follow up visit (approximately 90 days)Description: Cost of baking soda versus LithoLyte.
Measure: Cost of Treatment as measured by USD spent on the interventional drug Time: End of study (approximately 90 days)Description: Wisconsin Stone-QOL: answers range from a scale of 1-5, or yes/no Study Questionnaire: free text responses, or no/yes/I am no longer taking it
Measure: Patient acceptability Time: End of study (approximately 90 days)This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis to the urinary oxalate pool in obese calcium oxalate stone formers.
Description: Subjects will ingest a controlled diet low in oxalate and collect 2 x 24-hour urines before and after the Optifast VLCD Program. The utilization of a low oxalate diet allows assessment of the change in contribution of endogenous oxalate synthesis to the urinary oxalate pool.
Measure: Measurement of 24 hour urinary oxalate excretion Time: Day 4Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports